The LAA and Stroke in AF
AF is associated with mechanical dysfunction of atrial tissue. Loss of contractile function in the LAA can lead to local stasis and thrombus formation, which may then embolize into the systemic circulation. The observation that >90% of thrombi found in patients with nonvalvular AF and stroke are in the LAA supports this mechanistic sequence. 11 In addition, low Doppler inflow velocities, spontaneous echocardiographic contrast, and the presence of thrombus in the LAA have been associated with high stroke rates in AF patients. 12 These data lend support to the hypothesis that the elimination of the LAA may serve as a preventive strategy for AF-related stroke.
Morphological features of the LAA may influence stroke risk. Larger LAA neck diameter and LAA depth have been associated with a higher prevalence of prior stroke in AF patients. 13 A chicken wing shape appears to correlate less with prior embolic events than cauliflower, cactus, or windsock shapes, 14 but although this finding was reproduced in 1 small study, 15 it was disputed by another, larger study. 16 Such categorization of LAA morphology may be a poorly reproducible oversimplification of anatomy. The extent of trabeculations within the LAA may be a better predictor of thromboembolic events. 16 Therefore, LAA characteristics appear to influence stroke risk, but to date, there are no reproducible LAA features sufficiently validated for risk stratification. Stroke risk is influenced by a multitude of factors. Although the LAA is the most common site of thrombus in patients with nonvalvular AF and stroke, thrombi were identified only in the minority of such patients. 11 Although the offending thrombi could have embolized before LAA assessment, additional data suggest that not all strokes in AF may be prevented by LAA-targeted therapies. As many as 25% of strokes in AF patients can be linked to intrinsic cerebrovascular disease. 17 The CHADS 2 and CHA 2 DS 2 VASc scores are based on a particular individual's comorbidities (Tables 1 and 2 ). They can estimate a yearly risk of thromboembolic events 18, 19 and identify which patients may derive clinical benefit from anticoagulation, 20 yet they do not include parameters of LAA function or anatomy. Although hypertension and aortic atherosclerosis have been associated with an increased prevalence of LAA thrombus, spontaneous contrast, and low LAA inflow velocity, 21 the mechanistic connections between the LAA and many risk factors known to be predictive of stroke in AF remain to be fully elucidated. Despite these uncertainties, the LAA is a consistent and predictable site of origin of cerebral and systemic emboli in AF and thus constitutes an opportunity for stroke prophylaxis.
General Concepts for LAA Closure Device Evaluation
The appropriate assessment of transcatheter LAA devices requires a critical evaluation of the types of outcomes studied. Efficacy outcomes may include anatomic efficacy, that is, success of LAA closure on imaging studies, and clinical efficacy, that is, stroke prevention in the absence of oral anticoagulation. Although anatomic closure is commonly used as a surrogate for clinical efficacy, LAA closure may not guarantee long-term efficacy, whereas small residual leaks may not necessarily result in clinical failure. 22 Because the mechanism, material, and consequences of closure may differ between devices, clinical efficacy of 1 device may not necessarily translate into clinical efficacy of another device that has been shown to provide only anatomic closure. Safety outcomes are particularly important because LAA closure is a prophylactic procedure. The transcatheter devices share certain types of procedural complications (eg, vascular access bleeding, pericardial effusions, and air embolism), but the rates of complications may differ as a result of differences in implantation technique, device design, and operator experience.
Surgical LAA Exclusion and Excision
Madden 23 suggested >60 years ago that resection of the LAA could prevent recurrent arterial emboli caused by AF. Surgical exclusion or removal of the LAA during cardiac surgery in AF patients is now commonplace and forms in part the rationale for the development of transcatheter approaches to LAA closure. However, surgical LAA closure frequently appears to be incomplete, and residual flow may be associated with thromboembolic events. In the pilot Left Atrial Appendage Occlusion Study (LAOOS), 34% of patients had residual flow into the LAA after surgical exclusion. 24 Imaging studies of patients after surgical exclusion or excision have also documented relatively high rates of incomplete closure, although it is least frequent with LAA excision. [25] [26] [27] [28] The findings of observational studies that have examined the association between surgical LAA closure and stroke reduction are conflicting. 28, 29 A large, randomized trial examining the clinical efficacy of surgical LAA closure for stroke prevention is currently ongoing. 30 Devices to improve anatomic closure of the LAA during surgery have been developed. The AtriClip (Atricure, West Chester, OH) consists of 2 parallel titanium tubes and 2 nitinol springs with a knit-braided polyester fabric 31 delivered with a deployment tool consisting of a distal articulating head connected to a shaft and proximal actuator. The US Food and Drug Administration (FDA) approval states that it is indicated for LAA occlusion under direct visualization in conjunction with other open cardiac surgical procedures. The Exclusion of Left Atrial Appendage With AtriClip Exclusion Device in Patients Undergoing Concomitant Cardiac Surgery (EXCLUDE) study was a prospective observational study that examined device safety and anatomic closure in 71 patients undergoing concomitant cardiac surgery via a median sternotomy. 32 There were no device-related adverse events, and LAA closure was achieved in 95% of patients who completed 3-month imaging follow-up. However, efficacy data for stroke prevention in the absence of oral anticoagulation are lacking. Successful standalone thoracoscopic implantation of the AtriClip has been reported. 33 The safety and anatomic efficacy of such a minimally invasive approach in AF patients with contraindications to anticoagulation are being evaluated in the observational Stroke Feasibility Study (http://www.clinicaltrials.gov; NCT01997905).
Transcatheter Closure Strategies

PLAATO
The PLAATO system was the first transcatheter device developed for the purpose of LAA closure. 34 The device consisted of a self-expanding nitinol cage covered with an expanded polytetrafluoroethylene membrane. Device feasibility was evaluated in a nonrandomized, multicenter study of 64 patients who were at high thromboembolic risk but were not candidates for warfarin. 35 There was a high rate of anatomic closure at the time of the procedure (residual flow ≤3 mm in 98%), and safety was excellent. At the 5-year follow-up, the observed rate of stroke or transient ischemic attack was 3.8%/y compared with an expected rate of 6.6% based on the CHADS 2 score of the study population. Although this device was not evaluated further, the PLAATO experience serves as a proof of principle for device occlusion of the LAA for stroke prevention.
WATCHMAN
Device Characteristics
The WATCHMAN (Boston Scientific, Natwick, MA) consists of a self-expanding nitinol frame and membrane cap ( Figure 1 ). The device is delivered through a 14F sheath placed within the LAA, guided by a combination of fluoroscopy and transesophageal echocardiography (TEE; Figure 2 ).
Clinical Data
The safety and clinical efficacy of the WATCHMAN have been examined in 2 randomized, clinical trials; a nonrandomized, continuing-access registry was performed for the purpose of evaluating device and procedural safety ( recommended according to society guidelines. In PREVAIL, a minimum of 20% of patients were required to be enrolled at sites without prior WATCHMAN experience. Otherwise, the enrollment criteria for the 2 trials were similar. Patients were randomly assigned to either device implantation or warfarin therapy in a 2:1 fashion. Patients allocated to device implantation were treated with 6 weeks of warfarin and aspirin, at which time a follow-up TEE was performed. If the TEE findings were adequate (ie, no thrombus and peri-device leak<5 mm), warfarin was discontinued, and aspirin and clopidogrel were prescribed for 5 more months, followed by aspirin indefinitely. Both trials used bayesian statistics, which is an approach to combining prior information with current information as it accumulates.
Efficacy
In the PROTECT-AF trial, the WATCHMAN was noninferior to warfarin for the primary end point of cardiovascular/unexplained death, any stroke, or systemic embolism at 1065, 36 1588, 37 and at 2621 patient-years of follow-up 38 ( Table 1) . At 2621 patient-years, the WATCHMAN met the criterion for superiority. All-cause mortality was significantly reduced with the WATCHMAN at this late follow-up (hazard ratio, 0.66; 95% confidence interval, 0.45-0.98; frequentist P=0.038).
There was a significant improvement in quality-of-life measures in patients assigned to the WATCHMAN compared with those assigned to warfarin therapy. 40 Limitations of these analyses include a greater rate of voluntary withdrawal in the warfarin arm; a higher rate of hemorrhagic stroke in the warfarin-treated patients compared with prior experiences; inclusion of patients with CHADS 2 score of 1, who may not require anticoagulation; and a relatively large noninferiority margin, although the observed upper bound of the 95% credible interval during follow-up was substantially below this margin.
In the smaller PREVAIL trial, the 18-month rates of the coprimary end point of cardiovascular death, any stroke, or systemic embolism were numerically similar between Figure 1 . WATCHMAN device. The WATCHMAN device is made of a self-expanding nitinol frame with a polyethylene terephthalate fabric cap. Distal tines secure the device within the left atrial appendage (LAA) trabeculae. The device is fully retrievable before release from the delivery cable. Device length is approximately equal to its diameter. Device size is selected on the basis of the largest diameter of the LAA ostium, which is measured by drawing a line from the mitral valve annulus across to the ridge of left upper pulmonary vein, perpendicular to the planned axis of the delivery sheath. Alternatively, the LAA ostium can be measured from the mitral valve annulus to a point ≈2 cm distal from the tip of the left upper pulmonary vein ridge. WATCHMAN and warfarin, but the device did not achieve noninferiority because the upper bound of the 95% credible interval for the 18-month rate ratio was not lower than the prespecified noninferiority margin of 1.75 (Table 1 ). This finding should be interpreted in the context of a lower-than-expected event rate, particularly among the patients assigned to warfarin, and the relatively short duration of follow-up.
Further analyses support the mechanistic hypothesis that LAA occlusion reduces thromboembolic risk in the absence of oral anticoagulation. Landmark analyses of PROTECT-AF confined to the periods after the procedure and after termination of warfarin and clopidogrel therapy in the device arm demonstrated that the primary end point and ischemic stroke rates were similar in the patients receiving the WATCHMAN compared with those treated with warfarin. 37, 38 In PREVAIL, WATCHMAN implantation was noninferior to warfarin for the coprimary end point of ischemic stroke or systolic embolism occurring >7 days after randomization (Table 1) .
Safety
In PROTECT-AF, the rate of the major safety end point (excessive bleeding or a procedure-related complication) at 18 months was greater in the patients assigned to the WATCHMAN compared with warfarin (rate ratio, 1.69; 95% credible interval, 1.01-3.19), driven by pericardial effusions and procedure-related ischemic stroke. 36, 41 Most safety events in the device arm occurred within the first 7 days after the procedure. 41 These observations led in part to the conduct of the PREVAIL trial to determine whether the procedural modifications instituted during PROTECT-AF, combined with enhanced operator training, would lead to an improved safety profile. However, ongoing follow-up provides insight into the temporal risks and benefits of LAA closure with the WATCHMAN: Over the longer term, the difference in the cumulative rate of safety events narrowed between treatment groups as a result of bleeding events in the warfarin arm so that, at 2621 patient-years of follow-up, there was no significant safety difference between the WATCHMAN and warfarin (rate ratio, 1.17; 95% credible interval, 0.78-1.96). 38 In PREVAIL, new operators without prior WATCHMAN experience enrolled 39% of the patients. Despite the technical inexperience of these investigators, the WATCHMAN met the safety performance goal prespecified by the sponsor and the FDA. Safety events related to the procedure, including the incidence of serious pericardial effusions and procedural stroke, were significantly reduced compared with PROTECT-AF (Table 4) . Implantation by new operators was not associated with reduced rates of implantation success or an increased risk of major adverse events. This improved safety profile was consistent with the findings of the continuing-access registry that followed the PROTECT-AF trial. 41 
Anatomic Closure
Peri-device flow into the LAA is not uncommon after WATCHMAN implantation. In PROTECT-AF, flow around the device was detected by TEE in 41% and 32% of patients 39 Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation.
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at 6 weeks and 1 year after the procedure, respectively. 22 In a post hoc analysis, there was no association between clinical events and the presence of peri-device flow, regardless of size and whether warfarin was continued. 22 This analysis has limited power because of a small number of events. Whether residual leaks are clinically important with other devices is unknown and may depend on the mechanism of closure. 42 predominantly because of prior bleeding. Patients were treated with clopidogrel for 6 months and aspirin indefinitely after implantation. At a mean followup of 14.4±8.6 months, the observed rate of stroke or systemic embolism was 2.3%/y, significantly less than the expected rate of 7.3%/y based on CHADS 2 score. Important limitations of this study include its nonrandomized design, the small number of patients enrolled, and the use of an expected stroke rate as the comparator. In addition, dual antiplatelet therapy with aspirin and clopidogrel is associated with a bleeding hazard similar to that of warfarin in anticoagulant-eligible patients. 43 Therefore, the relative safety of this medical regimen in patients at very high bleeding risk is not known. A larger data set is required to adequately define the role and appropriate postprocedural medical regimen of LAA occlusion with the WATCHMAN in patients who cannot tolerate OACs as a result of prior bleeding or other contraindications.
Other Data
Stroke prevention strategies are particularly challenging in patients in whom anticoagulation is contraindicated. ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology (ASAP) was a prospective, multicenter, observational study that examined clinical outcomes with the WATCHMAN device in 150 AF patients who were ineligible for warfarin,
Amplatzer Cardiac Plug
Device Characteristics
The Amplatzer Cardiac Plug (St. Jude Medical, Minneapolis, MN) has CE mark and is not approved for use in the United States at this time. It is a self-expanding nitinol mesh that consists of a distal lobe and proximal disk, each with a sewn polyester patch, connected by a short central waist (Figure 3) . 44, 45 The proximal disk covers the mouth of the LAA from within the left atrium; therefore, the mechanism of LAA occlusion differs from that of the WATCHMAN, which occludes the LAA from within the appendage itself. The device is delivered from the femoral vein via a transseptal puncture using a combination of fluoroscopic and TEE guidance.
Clinical Safety and Efficacy
Clinical data with the Amplatzer Cardiac Plug are derived from several small, observational studies, many of which are retrospective in design or involve a single center or operator (Table 5) . 44, [46] [47] [48] [49] [50] [51] [52] Most of the patients enrolled in these studies had intolerance of or contraindications to OAC and were treated with aspirin and clopidogrel during the postprocedural period. The most frequent safety events appear to be pericardial effusions and device embolization, occurring at rates similar to those of the WATCHMAN experience. Although these observational findings are encouraging, a large, monitored, preferably randomized trial is necessary to robustly assess safety and efficacy because the mechanisms of implantation and closure differ from those of the WATCHMAN. A large, randomized, clinical trial of the Amplatzer Cardiac Plug compared with OAC (http://www.clinicaltrials.gov; NCT01118299) was recently halted, likely because of the anticipated FDA approval of the WATCHMAN, which would make it difficult to enroll patients in such a trial.
Lariat Procedure
Device Characteristics
The Lariat device (SentreHeart, Redwood City, CA) enables the transcatheter ligation of the LAA through the delivery of a surgical suture via a combined transseptal and subxiphoid approach 53, 54 ( Figure 4 ). The device is 510K-cleared by the FDA for the approximation of soft tissue, although it has been applied clinically to LAA ligation. Preprocedural cardiac computed tomography imaging is mandatory to assess anatomic eligibility: Appendages with diameter >40 mm, that have lobes behind the pulmonary artery, or that are posteriorly oriented should be avoided. A micropuncture or 17-gauge epidural needle is used to advance a guide wire and then a 14F sheath into the pericardial space. Therefore, unique to the Lariat, procedural complications can arise related to dry pericardial access. Transseptal puncture is then performed via the femoral vein. A magnet-tipped guide wire is advanced into the anterior aspect of the LAA, and a complementary magnet-tipped guide wire is advanced into the pericardium through the pericardial sheath to form a connection with the magnet-tipped wire in the LAA, over which the Lariat snare is advanced and closed at the LAA ostium with the use of TEE Figure 3 . Amplatzer Cardiac Plug. The Amplatzer Cardiac Plug is a self-expanding nitinol device consisting of a distal lobe and proximal disk with sewn-in polyester fabric connected by a central waist. The distal lobe has hooks around its circumference and anchors the device within the appendage, while the disk is positioned proximally along the plane of the tip of the left upper pulmonary venous ridge and the mitral valve annulus, thereby occluding the mouth of the left atrial appendage (LAA). Device size is selected on the basis of the maximal diameter of the distal lobe landing zone, measured ≈10 mm distal to the LAA orifice. A second-generation device has a slightly longer distal lobe, more stabilizing hooks, a longer central waist, and a larger-diameter proximal disk to facilitate implantation and to improve LAA sealing.
and fluoroscopic guidance. This snare contains a preloaded surgical knot, which is released with a proximal actuator and then tightened with a suture-tensioning device, after which the snare is removed and the suture is cut with a suture cutter. The pericardial sheath is exchanged for a drain, which is generally left in place for at least 4 to 6 hours.
Clinical Safety and Efficacy
To date, the safety and efficacy of LAA closure with the Lariat have been limited to a very few small, observational studies. 55, 56 In the largest reported prospective experience, Bartus et al 55 conducted a single-center, nonrandomized study that enrolled 92 patients who were poor candidates or ineligible for warfarin therapy. The procedure was aborted in 3 patients (3.2%) because of unexpected pericardial adhesions. Successful closure (residual leak<1 mm) was achieved in 96% of cases. Procedural complications, all of which were significant pericardial effusions, occurred in 3 patients, and pericarditis occurred in 2 patients. At the 1-year follow-up, 55% of the patients remained on warfarin therapy, and there were no thromboembolic events. A multicenter, retrospective study examined the early safety and efficacy of LAA closure with the Lariat device in 154 patients undergoing the procedure in the United States. 57 Device success (suture deployment and <5-mm leak by postprocedural TEE) was 94%. Procedure-related major bleeding occurred in 9.1% and a significant pericardial effusion occurred in 10.4% of patients. Thrombus at the site of Lariat ligation has also been reported, 58,58a but the actual rate of thrombus is unknown. Late leaks have been observed, but the clinical implications of such leaks are unclear. 59 In summary, from the small amount of data available, the Lariat appears to provide high rates of acute anatomic closure, although procedural morbidity, driven by bleeding events, pericardial effusions, and pericarditis, is not uncommon. Clinical efficacy data are absent. Several other questions about the Lariat remain unanswered, including whether safety events can be reduced with increased operator experience and what postprocedural medical therapy is required (ie, a brief duration of antiplatelet or anticoagulation therapy).
Other Devices
Several other LAA closure devices are currently in development. The WaveCrest LAA occluder (Coherex Medical, Salt Lake City, UT) is unique in that device implantation is a 1-step process. First, the proximal expanded polytetrafluoroethylene cap/occluder is positioned, and then the distal anchors are deployed. Incorporation of foam into the edges of the occluder could potentially enhance LAA sealing. This device currently has a CE mark, and initiation of a pivotal trial within the United States is planned. The LAmbre LAA occluder (Lifetech Scientific Corp, Shenzhen, China) 60 is a self-expanding nitinol device consisting of a distal, hookembedded umbrella and a proximal covering disk, both with sewn-in polyethylene terephthalate fabric. A short, articulating central waist connects the umbrella and cover.
Unresolved Questions Reservoir and Hormonal Functions of the LAA
The LAA is more compliant than the main left atrial chamber and appears to play an important role in left atrial pressure and volume overload. 61 In theory, LAA closure may negatively affect left atrial function and induce left atrial diastolic dysfunction by eliminating this reservoir function. In addition, LAA resection may reduce circulating atrial natriuretic peptide levels, resulting in fluid retention. 62 The effects on left atrial reservoir and hormonal function may differ among occlusion techniques (eg, filter occlusion versus acute ligation and necrosis of the LAA tissue). Studies of LAA closure to date have not specifically addressed these issues.
Operator Qualifications
There has been much debate whether interventional cardiologists or electrophysiologists should be performing transcatheter LAA closure. The relevant factor is proficiency in performing the necessary procedural steps. Keys to successful transcatheter LAA closure include competency performing transseptal puncture, understanding of the 3-dimensional anatomy of the left atrium and LAA and their echocardiographic and fluoroscopic correlates, specific training for each device, and competency in managing complications specific to LAA closure, including pericardiocentesis and retrieval of embolized devices.
Cost Considerations
Quantification of the cost of LAA closure must take into consideration the potential complications of each specific closure strategy, the costs associated with treatment of such complications, and the frequency and cost of treatment failure compared with those of standard of care, OAC. Data from randomized clinical trials serve as a reference to estimate event probabilities. Because randomized, clinical trial data are available only for the WATCHMAN, cost-effectiveness analysis is available only for this device. Singh et al 63 performed a cost-effectiveness analysis of the WATCHMAN compared with dose-adjusted warfarin and with dabigatran using published data available from the Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) and PROTECT-AF. Compared with warfarin, the incremental cost-effectiveness ratio was $46 560 per quality-adjusted life-year for dabigatran and $41 565 per quality-adjusted life-year for WATCHMAN. A cost of up to $50 000 per quality-adjusted life-year is commonly accepted in industrialized societies; therefore, a stroke prevention strategy with the WATCHMAN was considered cost-effective compared with warfarin and preferable to dabigatran. The increased safety of WATCHMAN implantation since PROTECT-AF 41 Figure 6 . Net clinical benefit of WATCHMAN compared with warfarin therapy. Benefit was defined as a weighed sum of outcome differences between warfarin and WATCHMAN. Because of procedural complications with device implantation, net benefit was achieved at ≈9 months after the procedure in WATCHMAN Left
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could further improve its cost-effectiveness, whereas it may be diminished if the price point of the WATCHMAN is substantially greater than the $8500 used in the study. Data on the costeffectiveness of the WATCHMAN compared with apixaban, rivaroxaban, or edoxaban are lacking.
Patient Selection
The incorporation of LAA closure into a stroke prevention strategy relies on the assessment of 3 competing hazards for a particular patient: the long-term risk of thromboembolic events without therapy (eg, CHADS 2 and CHA 2 DS 2 VASc scores), the short-term procedural risk of LAA closure, and the long-term bleeding risk on indefinite anticoagulation therapy (eg, HAS-BLED score) 64 ( Figure 5 ). Other factors that must be considered include patient compliance, patient preference, and contraindications to OAC. In PROTECT-AF, net clinical benefit favored the WATCHMAN at ≈9 months after implantation according to an analysis using a weighted sum of annualized event rates ( Figure 6 ). 65 Benefit was achieved earlier in the Continued-Access Protocol registry because of the significant reduction in procedural complications. 41 Patients with higher bleeding risk, diabetes mellitus, age ≥75 years, and a prior embolic event had greater net benefit with WATCHMAN implantation. Given the available data, it would appear that the most attractive population for LAA closure is made up of patients at moderate to high risk for ischemic stroke and who are at moderate to high, but not prohibitive, bleeding risk with OAC. Patients with longer life expectancy may particularly suitable because the net clinical benefit of closure would be expected to increase over time. Patient preference should help guide treatment selection in those who are at moderate to high thromboembolic risk but are excellent candidates for OAC, after appropriate education about the large body of safety and efficacy data for the novel OACs, against which LAA closure has not been evaluated. There is a paucity of robust data on the clinical safety and efficacy of LAA closure in patients who are not candidates for anticoagulation. The 2012 European Society of Cardiology guidelines for the management of AF provide a Class IIB recommendation (Level of Evidence B) that transcatheter LAA closure may be considered in patients with high stroke risk and contraindications for long-term OAC. 66 In a survey of European centers performing LAA closure, the most common indication for closure was an absolute contraindication to long-term anticoagulants. 67 However, such patients were not included in the randomized, clinical trials of LAA closure, and further study is required to confirm whether antiplatelet therapy alone after closure is safe in such patients and is effective in preventing device or remnant LAA thrombus. Finally, because procedural complications and efficacy are inherent and specific to each device, assumptions about a generic clinical benefit of LAA closure are not valid. More prospective, clinical outcomes data, preferably from randomized trials, are required for LAA closure devices other than the WATCHMAN before they can be integrated into an overall strategy for stroke prevention.
Conclusions
AF is increasing in prevalence worldwide. OACs, despite their proven efficacy, have several limitations and are associated with bleeding risk. Although the mechanism of thromboembolism in AF is multifactorial, the LAA appears to be the major source of thrombus and is a target for transcatheter interventional therapy with device occlusion or ligation. The WATCHMAN has the largest data set for clinical end points, having been evaluated in 2 randomized trials and an FDAmonitored continuing-access registry in warfarin-eligible patients. In total, these studies support the clinical efficacy of the WATCHMAN in preventing thromboembolic events in the absence of anticoagulation and, in turn, provide mechanistic support for the concept of LAA closure for stroke prevention in at-risk patients. However, extrapolating these findings to other LAA devices is perilous because there are limited safety data and a paucity of robust clinical outcomes data for alternative approaches to LAA closure. Patient selection for the WATCHMAN device should be guided by an assessment of thromboembolic and bleeding risk, in addition to patient preference. The role of LAA closure in patients with absolute contraindications to anticoagulation is not well defined outside small, observational studies and represents an important priority for future study.
